Vyleesi (Bremelanotide) Safety in Older Adults Aged 50 to 64

What Bremelanotide Does and Why Age Matters

Bremelanotide is a synthetic melanocortin-4 receptor (MC4R) agonist that acts centrally in the hypothalamus to modulate sexual desire pathways. The FDA approved it in June 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized HSDD not explained by a medical or psychiatric condition, relationship problems, or medication effects 1.

Age matters because the 50-to-64 bracket introduces variables the original trials were not powered to isolate. The RECONNECT phase 3 program enrolled women aged 18 to 56 (mean age ~39), meaning adults at the upper boundary of the current cohort had minimal representation 1. Cardiovascular baselines shift after age 50. Roughly 60% of U.S. women aged 55 to 64 have hypertension, according to National Health and Nutrition Examination Survey (NHANES) data published by the CDC 2. That statistic alone changes the risk calculus for a drug that transiently raises blood pressure with every dose.

Perimenopause, which typically begins in the mid-40s and may extend into the early 50s, adds hormonal complexity. Declining estradiol levels independently reduce libido, meaning the diagnosis of HSDD in this window requires careful exclusion of menopause-related desire loss before attributing symptoms to a condition bremelanotide can treat 3.

Blood Pressure and Heart Rate: The Primary Safety Signal

Transient cardiovascular changes are the most clinically relevant safety concern for older adults considering bremelanotide. In the RECONNECT trials, bremelanotide 1.75 mg produced a mean systolic blood pressure increase of approximately 2.5 mmHg and a mean diastolic increase of roughly 1.5 mmHg, peaking about 2 to 4 hours post-dose and resolving within 12 hours 1. Heart rate decreased by about 2 to 3 beats per minute in the same timeframe.

Those numbers sound modest. They are modest in a 35-year-old with a resting BP of 118/72. They carry different weight in a 58-year-old with treated hypertension hovering at 138/86.

The FDA prescribing information states: "Bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease" 4. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends that "cardiovascular risk should be assessed before initiating any pharmacotherapy for HSDD, particularly in women over 45" 5. For patients in the 50-to-64 range, a baseline blood pressure reading and, where indicated, a more thorough cardiovascular workup should precede the first injection.

Home blood pressure monitoring after the initial dose can help quantify individual response. If the post-dose systolic reading exceeds 150 mmHg or rises more than 10 mmHg above baseline, the prescribing clinician may need to reconsider continued use.

Nausea: Frequency, Severity, and Practical Management

Nausea is the most commonly reported adverse event with bremelanotide. In the pooled RECONNECT data, 40.0% of women in the bremelanotide group experienced nausea versus 1.3% in the placebo group 1. That is a number needed to harm (NNH) of roughly 2.6 for any nausea event.

About 13% of participants rated the nausea as moderate or severe. The symptom typically began within 30 to 45 minutes of injection and resolved in 2 to 3 hours. Drop-out rates due to nausea were around 7% in the active arm.

For older adults, nausea carries additional consequences. Women aged 50 to 64 are more likely to be taking medications where vomiting creates absorption risks, including oral anticoagulants, thyroid replacement, and antihypertensives. A missed dose of warfarin or levothyroxine due to emesis within an hour of ingestion is a clinical event, not a minor inconvenience.

Practical mitigation strategies include taking the injection on a light stomach (not fasting, not after a heavy meal), pretreatment with ondansetron 4 mg orally 30 minutes before the bremelanotide dose if nausea was significant on the first attempt, and scheduling timed medications at least 3 hours apart from anticipated bremelanotide use. The FDA label does not recommend routine antiemetic prophylaxis, but clinicians managing older patients with polypharmacy may find it a reasonable precaution.

Polypharmacy Interactions in the 50-to-64 Age Group

Adults aged 50 to 64 take a median of four prescription medications, based on data from the CDC's National Center for Health Statistics 6. Bremelanotide's pharmacokinetic profile offers some reassurance: it is not extensively metabolized by cytochrome P450 enzymes and shows limited protein binding 4.

There is one specific interaction with clinical teeth. Bremelanotide slows gastric emptying. The FDA label warns that it may reduce the rate and extent of absorption of orally administered medications 4. For drugs with narrow therapeutic windows, including naltrexone, certain oral antihypertensives, and oral hormonal contraceptives, the delayed absorption could produce either a subtherapeutic trough or a delayed peak.

Dr. Sheryl Kingsberg, one of the RECONNECT trial investigators, noted in a 2019 Obstetrics & Gynecology editorial that "the gastric emptying effect should prompt clinicians to review the full medication list before prescribing bremelanotide, particularly in patients taking time-sensitive oral therapies" 7.

Drugs that themselves lower blood pressure (alpha-blockers, nitrates, PDE5 inhibitors used by a male partner and inadvertently shared) pose a theoretical additive risk when combined with bremelanotide's hemodynamic effects, though no formal interaction studies with antihypertensives have been published.

Perimenopause, Hormonal Context, and Diagnostic Clarity

Bremelanotide's FDA-approved indication is limited to premenopausal women. Many women between 50 and 54 are technically still premenopausal or in early perimenopause, defined by the Stages of Reproductive Aging Workshop (STRAW+10) criteria as irregular menstrual cycles with a cycle-length variability of 7 or more days 8.

The distinction matters because reduced sexual desire in perimenopause is often driven by declining estradiol and testosterone levels rather than the neurobehavioral pattern that defines HSDD. The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care algorithm recommends that clinicians "first address hormonal contributors, relationship factors, and medication-induced causes before diagnosing HSDD" 9.

If a perimenopausal woman's low desire correlates temporally with hot flashes, vaginal dryness, and FSH levels above 25 mIU/mL, hormone therapy may be the more targeted intervention. If desire remains low after adequate estrogen replacement and genitourinary symptoms have resolved, then HSDD becomes a more defensible diagnosis and bremelanotide a more appropriate option.

For women aged 55 to 64 who are clearly postmenopausal (12+ months of amenorrhea), bremelanotide is off-label. No randomized trial has evaluated its efficacy or safety in this group specifically. Off-label prescribing is legal and sometimes reasonable, but both prescriber and patient should understand that the evidence base thins considerably past menopause.

Skin Hyperpigmentation and Other Age-Relevant Side Effects

Bremelanotide activates melanocortin-1 receptors (MC1R), the same receptor pathway that determines skin and hair pigmentation. In clinical trials, focal darkening of the face, gums, and breasts was reported in up to 1% of patients and did not always resolve after drug discontinuation 4.

For older adults already managing age-related hyperpigmentation (melasma, lentigines), additive darkening could be cosmetically significant or, more importantly, could mask melanoma surveillance. Dermatologic baseline documentation of existing pigmented lesions before starting therapy is a practical step, especially for fair-skinned patients or those with a personal history of dysplastic nevi.

Other side effects reported at rates above 2% in the RECONNECT trials included flushing (20.3% vs. 1.5% placebo), injection site reactions (5.4%), and headache (11.3% vs. 6.3% placebo) 1. Flushing may be more distressing in perimenopausal women already experiencing vasomotor symptoms, as it can compound the discomfort of hot flashes.

The 8-Dose Monthly Ceiling: Why It Exists

The FDA label caps bremelanotide at 8 doses per month. This limit exists because the RECONNECT trials tested the drug on an as-needed basis and most participants used it 2 to 4 times monthly. Long-term safety data beyond 12 months of open-label extension exposure is limited 10.

For older adults, the dose ceiling also functions as an indirect cardiovascular safeguard. Each injection produces a 12-hour window of hemodynamic perturbation. Eight doses per month means up to 96 hours of slightly elevated systolic pressure, a cumulative exposure that grows more meaningful with age-related arterial stiffening.

Patients who find themselves consistently approaching the 8-dose limit may benefit from reassessment. Either the drug is working well enough that daily pharmacotherapy (such as flibanserin) deserves discussion, or the drug is not producing adequate effect and continued use should be questioned.

Monitoring Recommendations for Prescribers

No official geriatric-specific monitoring guideline exists for bremelanotide because the drug was not studied in older populations as a distinct cohort. Based on the pharmacology and the adverse event profile from RECONNECT, a reasonable monitoring approach for women aged 50 to 64 includes the following components.

Before the first dose: confirm blood pressure is controlled (below 140/90 at minimum, ideally below 130/80 per ACC/AHA 2017 guidelines 11), review the complete medication list for drugs affected by delayed gastric emptying, document baseline skin pigmentation, and verify that HSDD diagnosis is not better explained by menopausal hormone deficiency.

After the first dose: the patient should check blood pressure at home 2 to 3 hours post-injection and report the result. A systolic rise exceeding 10 mmHg warrants clinical reassessment.

At 3 months: reassess treatment response using a validated instrument such as the Female Sexual Distress Scale-Revised (FSDS-R) or the Female Sexual Function Index (FSFI). If the FSDS-R score has not improved by at least 3 points, continued use has limited justification.

At 12 months: repeat blood pressure assessment, inspect for skin hyperpigmentation changes, and re-evaluate the HSDD diagnosis in light of any menopausal transition that may have occurred during the interval.

How RECONNECT Data Apply (and Don't Apply) to This Age Group

The RECONNECT program comprised two identically designed phase 3 trials enrolling a combined 1,247 premenopausal women with HSDD 1. The co-primary endpoints were change from baseline in the FSDS-R desire domain score and the number of satisfying sexual events (SSEs) over 4 weeks.

Bremelanotide produced a statistically significant improvement in FSDS-R desire score (difference from placebo: -0.7 on the desire item, P<0.001) and a modest increase in SSEs (+0.5 events per month vs. placebo) 1. The clinical meaningfulness of that SSE improvement has been debated.

Dr. Anita Clayton, principal investigator on several HSDD treatment trials, stated: "The RECONNECT results confirmed that bremelanotide addresses the distress component of HSDD more robustly than it changes event frequency, which is consistent with how patients describe their experience of the disorder" 7.

The enrolled population had a mean age of approximately 39. Subgroup analyses by age were not published in the primary manuscript. Women over 50 represented a small fraction of the total cohort, meaning that confidence intervals for efficacy and safety in the 50-to-64 bracket are wider than those reported for the full population. The absence of a dedicated older-adult subgroup analysis is a genuine evidence gap, not a reason to withhold the drug, but a reason to set expectations carefully and monitor more closely.

Comparing Bremelanotide With Flibanserin in Older Adults

Flibanserin (Addyi), the only other FDA-approved HSDD pharmacotherapy, is a daily oral serotonin agonist/antagonist. Both drugs are indicated for premenopausal women, and neither has strong data in the 50-to-64 group.

Key differences relevant to older adults: flibanserin requires daily dosing (100 mg at bedtime) and carries an alcohol contraindication with risk of severe hypotension and syncope 12. For patients who drink alcohol, even occasionally, bremelanotide's as-needed dosing avoids that interaction entirely. Bremelanotide has no alcohol restriction.

On the other hand, flibanserin does not produce the nausea rates seen with bremelanotide (nausea incidence in flibanserin trials was approximately 10%, one-quarter of the bremelanotide rate). For patients where gastrointestinal tolerability or polypharmacy absorption timing is a primary concern, flibanserin may present a simpler daily routine, provided alcohol avoidance is feasible.

Neither drug has been tested head-to-head. The choice between them in an older patient typically comes down to whether the patient prefers on-demand dosing with higher nausea risk or daily dosing with alcohol restriction and a slower onset of effect (flibanserin takes 4 to 8 weeks to show benefit).